Oruka Therapeutics, Inc. 8-K

What Happened
Oruka Therapeutics (ORKA) announced on April 27, 2026 (8‑K filing) initial 16‑week results from its randomized, double‑blind, placebo‑controlled Phase 2a EVERLAST‑A trial of ORKA‑001 in moderate‑to‑severe psoriasis. The trial met its primary endpoint: 63.5% (40/63) of ORKA‑001 treated patients achieved PASI 100 (complete skin clearance) at Week 16 versus 4.8% (1/21) for placebo (p < 0.0001). Oruka issued a press release, posted a data presentation, and held a conference call/webcast on April 27, 2026 to discuss the data.

Key Details

• Primary endpoint: PASI 100 at Week 16 — 63.5% (40/63) for ORKA‑001 vs 4.8% (1/21) for placebo (p < 0.0001).
• Secondary efficacy: PASI 90 = 82.5% (treatment) vs 4.8% (placebo); IGA 0 = 63.5% vs 4.8%; IGA 0/1 = 84.1% vs 4.8%.
• Safety: Treatment‑emergent adverse events in 50.8% of ORKA‑001 patients vs 57.1% placebo; no serious TEAEs and no discontinuations in the ORKA‑001 arm; most common TEAE was upper respiratory tract infection (19.0% vs 14.3%); no injection site reactions reported.
• Dosing and follow‑up: EVERLAST‑A enrolled 84 patients (3:1 randomization to 600 mg at Weeks 0 and 4 vs placebo); responders at Week 28 are re‑randomized to either no dosing until recurrence (to test yearly/extended off‑treatment remission) or 300 mg every six months. Longer‑term EVERLAST‑A data expected H2 2026.
• Supporting data & next steps: Phase 1 PK/PD: single 600 mg dose maintained levels and IL‑23 pathway inhibition through 52 weeks, supporting potential annual dosing; EVERLAST‑B (Phase 2b, ~160 patients) is enrolling with topline data expected in 2027.

Why It Matters
These 16‑week results show high rates of complete skin clearance (PASI 100) and strong PASI 90/IGA responses versus placebo, which, if confirmed in larger trials, could position ORKA‑001 competitively among IL‑23 inhibitors. The safety profile reported is consistent with the IL‑23p19 class and showed no serious adverse events or discontinuations in the treatment arm. Importantly, Phase 1 PK data and the trial design aim to evaluate less‑frequent (potentially yearly) dosing, which could be a differentiator for patients and prescribers. Investors should note these are interim results from an ongoing program and the company’s filing contains forward‑looking statements about future trials, timing and regulatory plans.